C A Peschken1, J M Esdaile. 1. Department of Medicine, University of Manitoba, Winnipeg, Canada. cpeschken@exchange.hsc.mb.ca
Abstract
OBJECTIVE: To evaluate the prevalence, disease course, and survival of patients with systemic lupus erythematosus (SLE) in a population of over 120,000 North American Indians (NAI), and contrast the results to those in the non-Indian population. METHODS: The regional arthritis center database and the medical records of all rheumatologists, hematologists, nephrologists, and general internists with > 1 patient with SLE were searched for cases of SLE diagnosed between 1980 and 1996. A random survey of 20% of family physicians serving this population suggested that > 85% of all SLE cases were identified. Demographics, SLE Disease Activity Index (SLEDAI) scores, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage scores. clinical manifestations, and therapy for NAI were contrasted with the results in Caucasians (CAUC). RESULTS: We identified 257 cases meeting the ACR criteria for SLE diagnosed between 1980 and 1996. There were 49 NAI cases, resulting in a prevalence of 42.3/100,000, compared to a prevalence of 20.6/100,000 for the remainder of the population. NAI patients were younger at diagnosis, had higher SLEDAI scores at diagnosis, and had more frequent vasculitis, proteinuria and cellular casts. There were no treatment differences at diagnosis or at 2 years, but NAI patients were significantly more likely to receive treatment with prednisone or immunosuppressives at the last clinic visit. The NAI patients had similar damage scores at diagnosis, but significantly higher scores at 2 years and at the last clinic visit. NAI ethnicity increased the likelihood of death more than 4-fold. CONCLUSION: The prevalence of SLE was increased 2-fold in the NAI population. NAI patients had higher SLEDAI scores at diagnosis and more frequent vasculitis and renal involvement, required more treatment later in the disease course, accumulated more damage following diagnosis, and had increased fatality.
OBJECTIVE: To evaluate the prevalence, disease course, and survival of patients with systemic lupus erythematosus (SLE) in a population of over 120,000 North American Indians (NAI), and contrast the results to those in the non-Indian population. METHODS: The regional arthritis center database and the medical records of all rheumatologists, hematologists, nephrologists, and general internists with > 1 patient with SLE were searched for cases of SLE diagnosed between 1980 and 1996. A random survey of 20% of family physicians serving this population suggested that > 85% of all SLE cases were identified. Demographics, SLE Disease Activity Index (SLEDAI) scores, Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage scores. clinical manifestations, and therapy for NAI were contrasted with the results in Caucasians (CAUC). RESULTS: We identified 257 cases meeting the ACR criteria for SLE diagnosed between 1980 and 1996. There were 49 NAI cases, resulting in a prevalence of 42.3/100,000, compared to a prevalence of 20.6/100,000 for the remainder of the population. NAI patients were younger at diagnosis, had higher SLEDAI scores at diagnosis, and had more frequent vasculitis, proteinuria and cellular casts. There were no treatment differences at diagnosis or at 2 years, but NAI patients were significantly more likely to receive treatment with prednisone or immunosuppressives at the last clinic visit. The NAI patients had similar damage scores at diagnosis, but significantly higher scores at 2 years and at the last clinic visit. NAI ethnicity increased the likelihood of death more than 4-fold. CONCLUSION: The prevalence of SLE was increased 2-fold in the NAI population. NAI patients had higher SLEDAI scores at diagnosis and more frequent vasculitis and renal involvement, required more treatment later in the disease course, accumulated more damage following diagnosis, and had increased fatality.
Authors: Henry V Chung; Mark Riley; Jin K Ho; Benjamin Leung; Gareth P Jevon; Laura T Arbour; Colin Barker; Richard Schreiber; Eric M Yoshida Journal: Can J Gastroenterol Date: 2007-09 Impact factor: 3.522
Authors: S Sam Lim; A Rana Bayakly; Charles G Helmick; Caroline Gordon; Kirk A Easley; Cristina Drenkard Journal: Arthritis Rheumatol Date: 2014-02 Impact factor: 10.995
Authors: Elizabeth D Ferucci; M Catherine Schumacher; Anne P Lanier; Maureen A Murtaugh; Sandra Edwards; Laurie J Helzer; Lillian Tom-Orme; Martha L Slattery Journal: Arthritis Rheum Date: 2008-08-15
Authors: João Luiz Coelho Ribas; Shirley Ramos da Rosa Utiyama; Renato Mitsunori Nisihara; Maristela Boeira; Iara Taborda de Messias Reason Journal: Rheumatol Int Date: 2008-09-27 Impact factor: 2.631
Authors: Candace H Feldman; Linda T Hiraki; Jun Liu; Michael A Fischer; Daniel H Solomon; Graciela S Alarcón; Wolfgang C Winkelmayer; Karen H Costenbader Journal: Arthritis Rheum Date: 2013-03